Loading...
Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection
The relationships between upadacitinib, an oral selective Janus kinase 1 inhibitor, plasma exposures, and its efficacy (assessed by the American College of Rheumatology 20%/50%/70% responses over time) in moderate‐to‐severe active rheumatoid arthritis (RA) were characterized using data from 574 pati...
Na minha lista:
| Udgivet i: | Clin Pharmacol Ther |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6896251/ https://ncbi.nlm.nih.gov/pubmed/31194885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1543 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|